Genmab — November 2017
-
Hvis der skulle være tvivl om dara’s plads i myelomatose, så er her et fint overblik over mulighederne i RRMM https://twitter.com/vince
ntrk/status/927611793991782400 -
-
-
Iphone
-
Nice - tak Mads
-
God morgen herfra GC. 24 grader og solen er ved at dukke op bag ved klippen
-
-
this highlights the focus on measuring minimal residual disease (MRD) status -in the CANDOR study, Amgen /Janssen, comparing Kyprolis
(carfilzomib), Darzalex (daratumumab), and dexamethasone : http://www.businesswire.com/news/home/20171106005325/en/Adaptive-Biotechnologies-Announces-Collaboration-Amgen-Advance-Clinical
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind